Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aurobindo Co-Founder Hit With $3m Fine For Insider Trading

Indian stock market regulator SEBI has taken action over deals involving Pfizer

Executive Summary

Indian stock market regulator SEBI has slapped the billionaire founder of Aurobindo Pharma, along with other promoters of the company, with a more than $3m fine for allegedly violating insider trading norms over a string of licensing agreements with multinational Pfizer.

You may also be interested in...

Aurobindo Strikes New Chinese JV As Beijing’s Reforms Gain Pace

Aurobindo has formed a new joint venture with a Chinese partner to supply products for the world’s second-largest pharmaceutical market, as Beijing’s drug procurement reforms gather pace.

Aurobindo Faulted In US FDA Warning Letter For Poor Root Cause Investigations

Aurobindo failed to properly investigate problems with carcinogenic impurities in active pharmaceutical ingredients, warning letter says.

India’s Top Court Tells Singhs To Come Up With Plan To Pay Daiichi, Uphold Nation’s ‘Honor’

India’s Supreme Court has told Malvinder Singh and Shivinder Singh, once corporate billionaires, to work out a strategy within two weeks to pay Japanese drug giant Daiichi Sankyo a $500m arbitration award and "uphold the nation’s honor."


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts